Is AbbVie (ABBV) one of the Best Psychedelic Stocks to Buy in 2026?

AbbVie (NYSE:ABBV) is among the best psychedelic stocks to buy in 2026. AbbVie (NYSE:ABBV) expanded its psychiatry pipeline with the acquisition of psychedelic compound bretisilocin from Gilgamesh Pharmaceuticals in 2025. It paid $1.2 billion for bretisilocin, a Phase 2 psychedelic drug candidate being developed as a treatment for major depressive disorder. AbbVie has a broad portfolio of approved drugs and drug candidates targeting diverse health issues.

On March 12, Guggenheim reiterated its Buy rating and $242 on AbbVie (NYSE:ABBV) stock. For this renewed bullish stance, AbbVie, Guggenheim pointed to Skyrizi. The equity research firm is confident in the growth outlook for Skyrizi for many years to come. Guggenheim noted that while several drug candidates are being tested against Skyrizi, it sees little impact on Skyrizi sales. Moreover, the firm noted that AbbVie’s overall business is robust.

Previously, on March 9, William Blair reaffirmed its Outperform rating on AbbVie (NYSE:ABBV) stock, citing the potential of the company’s obesity drug candidate. The firm’s action came shortly after AbbVie announced topline results from a Phase 1 study of ABBV-295, an amylin analog drug candidate targeting obesity. According to William Blair, the results that ABBV-295 attained in that study are competitive in the amylin class.

AbbVie (NYSE:ABBV) is an American pharmaceutical company based in Illinois. It develops, manufactures, and sells drugs for a broad variety of medical issues. Its product portfolio includes treatments for various cancers and inflammatory diseases. It also makes skincare products. AbbVie is also making inroads in the psychedelic medicines space, bolstering its push in this area with its 2025 acquisition of Gilgamesh Pharmaceuticals’s psychiatry drug candidate.

While we acknowledge the risk and potential of ABBV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABBV and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.